131 related articles for article (PubMed ID: 25557064)
21. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological Analysis of Five Cases of NUT Midline Carcinoma, including One with the Gingiva.
Zhou L; Yong X; Zhou J; Xu J; Wang C
Biomed Res Int; 2020; 2020():9791208. PubMed ID: 32149149
[TBL] [Abstract][Full Text] [Related]
23. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.
Hainsworth JD; Infante JR; Spigel DR; Arrowsmith ER; Boccia RV; Burris HA
Cancer Invest; 2011 Aug; 29(7):451-5. PubMed ID: 21696296
[TBL] [Abstract][Full Text] [Related]
24. The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Schmitt S; Ho AD; Goldschmidt H
Onkologie; 2010; 33(4):183-6. PubMed ID: 20389145
[TBL] [Abstract][Full Text] [Related]
25. [A Case Report of Primary Pulmonary NUT Carcinoma and Literature Review].
Liu X; Li Y; Yu M; Zhou L
Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):63-68. PubMed ID: 33478193
[TBL] [Abstract][Full Text] [Related]
26. [Lung Cancer with Prominent Mediastinal Lymphadenopathy - Who Thinks of NUT Carcinoma?].
Keymel S; Krüger S
Pneumologie; 2020 Jan; 74(1):35-38. PubMed ID: 31918444
[TBL] [Abstract][Full Text] [Related]
27. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
Huang WJ; Tang YA; Chen MY; Wang YJ; Hu FH; Wang TW; Chao SW; Chiu HW; Yeh YL; Chang HY; Juan HF; Lin P; Wang YC
Cancer Lett; 2014 Apr; 346(1):84-93. PubMed ID: 24355296
[TBL] [Abstract][Full Text] [Related]
28. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
[TBL] [Abstract][Full Text] [Related]
29. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.
Ossenkoppele GJ; Lowenberg B; Zachee P; Vey N; Breems D; Van de Loosdrecht AA; Davidson AH; Wells G; Needham L; Bawden L; Toal M; Hooftman L; Debnam PM
Br J Haematol; 2013 Jul; 162(2):191-201. PubMed ID: 23647373
[TBL] [Abstract][Full Text] [Related]
30. A case of endobronchial NUT midline carcinoma with intraluminal growth.
Watanabe S; Hirano S; Mine S; Yoshida A; Motoi T; Ishii S; Naka G; Takeda Y; Igari T; Sugiyama H; Kobayashi N
Anticancer Res; 2015 Mar; 35(3):1607-12. PubMed ID: 25750317
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.
Iwamoto M; Friedman EJ; Sandhu P; Agrawal NG; Rubin EH; Wagner JA
Cancer Chemother Pharmacol; 2013 Sep; 72(3):493-508. PubMed ID: 23820962
[TBL] [Abstract][Full Text] [Related]
32. NUT midline lung cancer: a rare case report with literature review.
Gupta R; Mumaw D; Antonios B; Anusim N; Dhulipalla SP; Stender M; Huben M; Jaiyesimi I
AME Case Rep; 2022; 6():2. PubMed ID: 35128310
[TBL] [Abstract][Full Text] [Related]
33. Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Kiliccioglu I; Konac E; Varol N; Gurocak S; Yucel Bilen C
Genet Mol Res; 2014 May; 13(2):3721-31. PubMed ID: 24854658
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
[TBL] [Abstract][Full Text] [Related]
35. NUT midline carcinoma with cutaneous metastases.
Young MR; Millington K; Clarke LE; Helm K
J Am Acad Dermatol; 2012 Aug; 67(2):323-4. PubMed ID: 22794811
[No Abstract] [Full Text] [Related]
36. A 48-Year-Old Male with Cutaneous Metastases of NUT Midline Carcinoma Misdiagnosed as Herpes Zoster.
Ko LN; Weng QY; Song JS; Asel M; Granter SR; Mostaghimi A
Case Rep Oncol; 2017; 10(3):987-991. PubMed ID: 29279703
[TBL] [Abstract][Full Text] [Related]
37. Nuclear protein in testis midline carcinoma in a Turkish boy: a case report.
Bayrak BY; Yildiz DK; Demirsoy U; Çorapçioğlu F; Anik Y; French CA
Asian Biomed (Res Rev News); 2020 Oct; 14(5):203-208. PubMed ID: 37551266
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors in cancer: what have we learned?
Whittle JR; Desai J
Cancer; 2015 Apr; 121(8):1164-7. PubMed ID: 25537232
[No Abstract] [Full Text] [Related]
39. NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity.
Salati M; Baldessari C; Bonetti LR; Messina C; Merz V; Cerbelli B; Botticelli A
Crit Rev Oncol Hematol; 2019 Dec; 144():102826. PubMed ID: 31707223
[TBL] [Abstract][Full Text] [Related]
40. The primary pulmonary NUT carcinomas and some uncommon somatic mutations identified by next-generation sequencing: a case report.
Liu Y; Li YY; Ke XX; Lu Y
AME Case Rep; 2020; 4():24. PubMed ID: 33178996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
